rhASB recombinant human arylsulfatase B regulatory update

BMRN's rhASB received EMEA Orphan Drug designation to treat mucopolysaccharidosis IV (MPS IV). The product, which has Orphan Drug and fast track designation in the U.S., is in U.S. Phase I trials (see...